CLEVELAND, Oct. 15, 2015 /PRNewswire/ -- ViewRay, Inc. (OTCQB: VRAY) announced today that the company will showcase its MRIdian system and new faster, higher resolution imaging at the 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO), which will be held October 18-21, 2015 in San Antonio. MRIdian, the world's first and only MRI-guided radiation therapy system that images and treats cancer patients simultaneously, will be featured in a number of presentations highlighting clinical experience, real-time targeting and adaptive therapy.
Many believe the future of radiation oncology lies inevitably in MRI-guided radiation therapy, making it a topic of great interest at this year's meeting. MRIdian will be the subject of 19 clinical presentations and posters presented as part of ASTRO's Scientific Sessions. Topics include the advantages of on-table adaptive treatment and outcomes in the treatment of bladder, abdomen and head and neck cancers. Two posters will highlight the value of MRIdian in delivering accelerated partial breast irradiation (APBI), including tighter margins for treatment delivery and improved cosmesis. A number of physics topics related to MRIdian will also be highlighted, such as treatment planning, contour tracking and commissioning. A full list of MRIdian-focused Scientific Session presentations is available at http://www.viewray.com/astro_2015.htm
"We're excited that so many users of the MRIdian system will be presenting at this year's ASTRO, illustrating the wide array of treatment indications for which MRI-guided radiation therapy is beneficial," said Chris A. Raanes, ViewRay® president and CEO. "With hundreds of patients now treated by MRIdian, some now 18 months post-treatment, ASTRO presents an excellent forum for the sharing of clinical experience and outcomes data."
Visitors to the company's booth #318 can receive a demonstration of MRIdian's new faster, higher-resolution imaging upgrade, which features twice its original speed now at eight frames per second. The MRI component of MRIdian captures soft tissue images of the patient's body simultaneously during treatment. The system was designed specifically for therapy with a split magnet to ensure geometric precision with high spatial integrity, accurate delivery of the dose as planned and continuous fast imaging without overheating the patient.
MRIdian users from Washington University and Siteman Cancer Center at Barnes-Jewish Hospital, University of California, Los Angeles Health System and Jonsson Comprehensive Cancer Center (UCLA) and The University of Wisconsin Carbone Cancer Center (University of Wisconsin) will present on their clinical experience and outcomes data in the ViewRay booth. The in-booth presentations will cover the use of MRI for accurate alignment, real-time on-table adaptive treatment and direct soft-tissue tracking. A detailed schedule of these presentations, which will take place at various times from Sunday, October 18 through Tuesday, October 20, is available on ViewRay's website at http://www.viewray.com/astro_2015.htm
ViewRay will also host one of ASTRO's Industry Expert Theater sessions, titled "Align, Adapt and Track Soft Tissues with MRI Guided Radiation Therapy, A New Clinical Paradigm," which will take place on Monday, October 19 at 3:45 p.m. in Hall B, Theater 1. This session features presentations by Michael Steinberg, M.D., from UCLA and John Bayouth, Ph.D., from the University of Wisconsin on their first year of clinical experience with MRIdian.
The MRIdian System, which has been treating patients since January 2014, is currently installed and treating patients at four leading cancer centers in the United States and abroad.
ViewRay, Inc. of Cleveland, Ohio, is a medical device company that develops advanced radiation therapy technology for the treatment of cancer. The MRIdian system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the presentations to be featured at ASTRO, the wide array of treatment indications for which MRI-guided radiation therapy is beneficial and the demonstration of the MRIdian upgrade at ASTRO. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize MRIdian, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC, available at www.sec.gov.
SOURCE ViewRay, Inc.